Durability of Glucose-Lowering Effect of the First Administration of Dulaglutide: A Retrospective, Single-Center, Single-Arm Study

INTRODUCTION: Dulaglutide (Dula) is a once-weekly glucagon-like peptide-1 receptor agonist that efficiently reduces the level of glycated hemoglobin (HbA1c) in patients with type 2 diabetes (T2D). However, the durability of the glucose-lowering effect of the first injection of Dula (1st Dula) remain...

Descripción completa

Detalles Bibliográficos
Autores principales: Matsushita, Maya, Chujo, Daisuke, Tonoike, Mie, Kajio, Hiroshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2018
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6167306/
https://www.ncbi.nlm.nih.gov/pubmed/30056503
http://dx.doi.org/10.1007/s13300-018-0474-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6167306/
https://www.ncbi.nlm.nih.gov/pubmed/30056503
http://dx.doi.org/10.1007/s13300-018-0474-5

Ejemplares similares